Callan Family Office LLC Buys Shares of 2,316 Axon Enterprise, Inc $AXON

Callan Family Office LLC bought a new stake in Axon Enterprise, Inc (NASDAQ:AXON) during the second quarter, HoldingsChannel.com reports. The institutional investor bought 2,316 shares of the biotechnology company’s stock, valued at approximately $1,298,000.

Several other large investors have also modified their holdings of AXON. Rockefeller Capital Management L.P. lifted its position in Axon Enterprise by 53.2% in the fourth quarter. Rockefeller Capital Management L.P. now owns 11,518 shares of the biotechnology company’s stock valued at $6,542,000 after purchasing an additional 4,002 shares during the period. Legal & General Group Plc increased its position in Axon Enterprise by 1.3% during the 4th quarter. Legal & General Group Plc now owns 426,533 shares of the biotechnology company’s stock worth $242,241,000 after purchasing an additional 5,419 shares during the period. Eurizon Capital SGR S.p.A. purchased a new position in shares of Axon Enterprise during the 4th quarter worth approximately $13,116,000. B. Metzler seel. Sohn & Co. AG purchased a new position in shares of Axon Enterprise during the 2nd quarter worth approximately $3,854,000. Finally, Arrowstreet Capital Limited Partnership acquired a new stake in shares of Axon Enterprise in the 1st quarter valued at approximately $15,067,000. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Insider Buying and Selling at Axon Enterprise

In related news, Director Jeri Williams sold 629 shares of the business’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $469.64, for a total value of $295,403.56. Following the sale, the director directly owned 1,141 shares in the company, valued at $535,859.24. The trade was a 35.54% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, President Joshua Isner sold 13,000 shares of the business’s stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $488.45, for a total transaction of $6,349,850.00. Following the completion of the sale, the president owned 169,125 shares in the company, valued at $82,609,106.25. This represents a 7.14% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 66,989 shares of company stock worth $35,216,932. Insiders own 4.20% of the company’s stock.

Axon Enterprise Stock Performance

NASDAQ AXON opened at $627.75 on Monday. Axon Enterprise, Inc has a 1-year low of $339.01 and a 1-year high of $794.29. The company has a market capitalization of $51.00 billion, a P/E ratio of 260.48, a PEG ratio of 10.19 and a beta of 1.39. The business has a 50 day moving average price of $543.11 and a 200 day moving average price of $476.99. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.15 and a quick ratio of 1.80.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings data on Tuesday, August 4th. The biotechnology company reported $1.88 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.84 by $0.04. The firm had revenue of $904.39 million during the quarter, compared to analysts’ expectations of $876.42 million. Axon Enterprise had a return on equity of 2.84% and a net margin of 6.19%.Axon Enterprise’s revenue was up 35.3% on a year-over-year basis. During the same period in the previous year, the firm posted $2.12 earnings per share. Sell-side analysts expect that Axon Enterprise, Inc will post 2.04 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently weighed in on the company. Morgan Stanley lifted their price target on Axon Enterprise from $600.00 to $640.00 and gave the company an “overweight” rating in a research note on Thursday, August 6th. JPMorgan Chase & Co. increased their price objective on Axon Enterprise from $750.00 to $755.00 and gave the stock an “overweight” rating in a research report on Thursday, May 7th. Needham & Company LLC reissued a “buy” rating on shares of Axon Enterprise in a report on Thursday, August 6th. TD Cowen restated a “buy” rating on shares of Axon Enterprise in a research report on Wednesday, July 22nd. Finally, Zacks Research cut shares of Axon Enterprise from a “strong-buy” rating to a “hold” rating in a research note on Friday, July 10th. Thirteen research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $730.92.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.